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Abstract
Background: With the exception of APOE e4 allele, the common genetic risk factors for sporadic Alzheimer’s Disease (AD)
are unknown.
Methods and Findings: We completed a genome-wide association study on 381 participants in the ADNI (Alzheimer’s
Disease Neuroimaging Initiative) study. Samples were genotyped using the Illumina Human610-Quad BeadChip. 516,645
unique Single Nucleotide Polymorphisms (SNPs) were included in the analysis following quality control measures. The
genotype data and raw genetic data are freely available for download (LONI, http://www.loni.ucla.edu/ADNI/Data/). Two
analyses were completed: a standard case-control analysis, and a novel approach using hippocampal atrophy measured on
MRI as an objectively defined, quantitative phenotype. A General Linear Model was applied to identify SNPs for which there
was an interaction between the genotype and diagnosis on the quantitative trait. The case-control analysis identified APOE
and a new risk gene, TOMM40 (translocase of outer mitochondrial membrane 40), at a genome-wide significance level
of#1026 (10211 for a haplotype). TOMM40 risk alleles were approximately twice as frequent in AD subjects as controls. The
quantitative trait analysis identified 21 genes or chromosomal areas with at least one SNP with a p-value#1026, which can
be considered potential ‘‘new’’ candidate loci to explore in the etiology of sporadic AD. These candidates included EFNA5,
CAND1, MAGI2, ARSB, and PRUNE2, genes involved in the regulation of protein degradation, apoptosis, neuronal loss and
neurodevelopment. Thus, we identified common genetic variants associated with the increased risk of developing AD in the
ADNI cohort, and present publicly available genome-wide data. Supportive evidence based on case-control studies and
biological plausibility by gene annotation is provided. Currently no available sample with both imaging and genetic data is
available for replication.
Conclusions: Using hippocampal atrophy as a quantitative phenotype in a genome-wide scan, we have identified candidate
risk genes for sporadic Alzheimer’s disease that merit further investigation.
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Introduction
Age is a major risk factor for Alzheimer’s disease (AD), and with
both life expectancy and population increases, its incidence is
expected to double in the next two decades [1]. Genetic
investigations have discovered some putative pathophysiological
mechanisms related to the accumulation of senile plaques and
neurofibrillary tangles, the histopathological hallmarks of AD. The
high incidence of dementia in Down’s syndrome and analysis of
the amino acid sequence of beta-amyloid has led to identification
of a series of mutations associated with increased amyloid
production. However, such mutations only account for a very
small percentage of Alzheimer cases. Risk factors have been
identified for the sporadic cases, which are the majority of AD
patients, although these factors collectively explain a relatively
modest amount of the genetic risk for AD [2]. The most significant
of these is the presence of apolipoprotein E4 (APOE e4). The most
commonly used strategies to find disease-related genes such as
APOE have been linkage studies and candidate gene association
studies. The late onset of Alzheimer’s disease and the sporadic
nature of most cases complicate family studies, although more
than a dozen have been performed [2]. These family studies and
the case-control studies strongly implicate multiple genetic loci in
susceptibility to AD [2]. Candidate gene approaches targeting
amyloid, tau, and inflammatory cascades have proved useful, yet
the identification of other major risk factors have proved elusive,
with few associations being replicated.
The recent availability of high-throughput genotyping has
allowed the simultaneous measurement of hundreds of thousands
to more than one million SNPs (Single Nucleotide Polymorphisms),
which has made genome-wide association studies (GWAS) feasible.
A major challenge in case-control GWAS designs in which allele
and genotype frequencies are compared between AD and control
patients is achieving sufficient statistical power. Such categorical
approaches require approximately 6,000 cases and controls to
obtain 85% power to detect a 30% difference (odds-ratio of 1.3) with
a minor allele frequency of 0.15 [3]. Quantitative trait association
studies offer several advantages over case-control studies, since the
dependent measures are quantitative and more objective than
diagnostic categorization, and can increase the statistical power four
to eight fold, thus greatly decreasing the required sample size to
achieve sufficient statistical power [4].
We present the results of a GWAS in the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) cohort, a longitudinal multi-site
observational study including AD, mild cognitive impairment
(MCI), and elderly individuals with normal cognition [5] assessing
clinical and cognitive measures, MRI and PET scans (FDG and
11C PIB) and blood and CNS biomarkers. Major goals of ADNI
are to make this wealth of data available to the general scientific
community and to improve methods for clinical trials by
optimizing methods for imaging that are associated with clinical
symptoms and the conversion of MCI to AD. The clinical and
imaging measures from this longitudinal study have previously
been made publicly available; the genome-wide genotyping results
for 793 subjects from the Illumina Human610-Quad BeadChip
(Illumina Corporation, San Diego, CA) as performed by The
Translational Genomics Research Institute (TGen, Phoenix, AZ),
are now also publicly available.
In this initial analysis of the AD and the healthy control subsets
of the data, we first performed a case control analysis and found
APOE as well as an associated gene TOMM40, that provides
additional risk for developing AD.
To complement the case-control/candidate gene approach to
discover new risk genes for AD we performed a QT (quantitative
trait) analysis. Our method uses the hippocampal grey matter
density from neuroimaging as the quantitative trait, and examines
which SNPs (as proxies for genes) influence the quantitative trait
differently for AD and healthy controls. The concentration of grey
matter in the hippocampus [6] was chosen as the QT phenotype
as it is affected early in AD, is implicated in the conversion to and
progress of AD [7,8] and is associated with many of the cardinal
symptoms, and it can be reliably measured in vivo. We used
differences in the total grey matter concentration of the
hippocampal area, (the four CA fields of the hippocampus proper,
plus dentate gyrus, subiculum, entorhinal cortex, and parahippo-
campal gyrus) in AD subjects vs normal aged-matched controls in
our model, since MRI studies have suggested that reductions in
hippocampus over time can be particularly useful in predicting AD
before the onset of clinical symptoms, and in assessing the efficacy
of pharmacological treatment in clinical trials [9–12]. Therefore,
in our GWA study we used hippocampal concentration as an
imaging phenotype to reveal genes that potentially influence
hippocampal atrophy and dementia in the context of AD. The
genes which influence hippocampal grey matter concentration
differentially in AD and healthy subjects may provide important
information regarding the mechanisms of disease-related atrophy.
The power of this approach is demonstrated in the results
implicating novel genes which have been implicated in candidate
neurodegenerative mechanisms.
Methods
Ethics
For the purpose of this analysis we used ADNI subject data that
was previously collected across 50 sites. Study subjects gave written
informed consent at the time of enrollment for imaging and
genetic sample collection and completed questionnaires approved
by each participating sites’ Intitutional Review Board (IRB).
ADNI
Data used in the preparation of this article were obtained from
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
(www.loni.ucla.edu\ADNI). The ADNI was launched in 2003 by
the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the Food and
Drug Administration (FDA), private pharmaceutical companies
and non-profit organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and clinical
and neuropsychological assessment can be combined to measure
the progression of mild cognitive impairment (MCI) and early
Alzheimer’s disease (AD). Determination of sensitive and specific
markers of very early AD progression is intended to aid
researchers and clinicians to develop new treatments and monitor
their effectiveness, as well as lessen the time and cost of clinical
trials.
The Principle Investigator of this initiative is Michael W.
Weiner, M.D., VA Medical Center and University of California –
San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from over
50 sites across the U.S. and Canada. The initial goal of ADNI was
to recruit 800 adults, ages 55 to 90, to participate in the research—
approximately 200 cognitively normal older individuals to be
followed for 3 years, 400 people with MCI to be followed for 3
years, and 200 people with early AD to be followed for 2 years.’’
For up-to-date information see www.adni-info.org.
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Participants
All subjects were part of the Alzheimer’s disease Neuroimaging
Initiative (ADNI), a longitudinal multi-site observational study
including AD, mild cognitive impairment (MCI), and elderly
individuals with normal cognition assessing clinical and cognitive
measures, MRI and PET scans (FDG and 11C PIB) and blood and
CNS biomarkers. Brain imaging, biological samples, and clinical
assessments are longitudinally collected for a target of 200 healthy
controls, 400 MCI, and 200 AD subjects. For the AD sample, the
study focuses on identification of sporadic cases of mild AD,
subjects between the ages of 55–90, with an MMSE score of 20–26
inclusive and meeting NINCDS/ADRDA criteria for probable
AD [13–15], and having an MRI consistent with the diagnosis of
AD. Major goals of ADNI are to make this wealth of data
available to the general scientific community and to improve
methods for clinical trials by optimizing methods for imaging that
are associated with diagnosis and clinical symptoms. In this
analysis we contrast the AD subjects with healthy controls. This
analysis is confined to baseline diagnosis and MRI scans for each
subject.
Following volumetric analysis and genotyping quality control
measures (described below), data from a total of 172 AD subjects
and 209 healthy controls were included in this analysis.
Procedures
MRI. The data collection methods have been described in
more detail in Jack et al., 2008 [16], and Mueller et al. 2005 [5].
The images analyzed here were the baseline or screening scans at
the entry to the study; they were collected using the standard ADNI
protocol on 1.5T GE, Siemens, or Philips MR scanners [16].
The analyzed datasets included the T1-weighted structural MRI
scans from all available subjects. Following the segmentation and
quality assurance defined below, a final dataset of 229 healthy
controls and 194 AD subjects provided grey matter concentration
estimates of the hippocampus, using a voxel-based morphometry
approach.
The MRI images were converted from DICOM format into
NIFTI format and re-oriented into MNI coordinate conventions
using FSL tools [17]. They were then registered with the MNI
brain atlas, corrected for intensity inhomogeneities and segmented
into 3 classes (grey matter (GM), white matter (WM), and CSF)
using the VBM toolbox integrated with the SPM5 package [6,18].
Datasets with an extreme value of computed total brain density
or the ratio of grey/white matter density were inspected, leading to
the exclusion of several datasets in which segmentation was
unsuccessful. Often, these were cases with large ventricles and/or
diffuse white matter hypointensities. When there were multiple
datasets per subject, the best segmentation for each subject was
selected, blind to diagnosis or gender. The datasets of all subjects
whose segmentation was successful were used to construct custom
templates for the class prior probabilities. These custom templates
were used in a second run to segment all datasets. To allow a
comparison with the previous run, the same datasets were selected
for further evaluation. Again, a quality check was performed using
the total brain density and the ratio of grey/white matter density.
The total grey matter was generally higher in this segmentation,
which is very much expected with a better-matched template.
The right and left hippocampal regions were defined using the
AAL brain atlas [19], and the mean of the grey-matter fraction
over voxels within those regions was computed for the final
imaging phenotypes on each subject.
Genotyping. Blood samples were obtained from each
participant and sent to Pfizer for DNA extraction. All DNA
extraction and genotyping was done blinded to group assignment.
Genotyping on the blinded DNA was performed by TGen using
the Illumina Human610-Quad BeadChip.
Approximately 200 ng of DNA was used to genotype each
subject sample according to the manufacturer’s protocol (Illumina,
San Diego, CA). After amplification, fragmentation and hybrid-
ization, the specifically hybridized DNA was fluorescently labeled
by a single base extension reaction and detected using a
BeadArray scanner. Non-specifically hybridized fragments were
removed by washing while remaining specifically hybridized DNA
were processed for the single base extension reaction, stained and
imaged on an Illumina Bead Array Reader. Normalized bead
intensity data obtained for each sample were loaded into the
Illumina BeadStudio 3.2 software which generated SNP genotypes
from fluorescent intensities using the manufacturer’s default cluster
settings. The data analyzed with BeadStudio are publicly available
on the LONI website (www.loni.ucla.edu/ADNI/Data). The raw
genotypic data were imported in a genome-wide data manage-
ment system, i.e. SNPLims [20], to allow the export of user-
defined formats compatible with the genetic programs used for the
statistical analysis.
The following Quality Control (QC) procedures were imple-
mented on the genome-wide data. We performed all data analysis
and QC using the PLINK software package (http://pngu.mgh.
harvard.edu/purcell/plink/), release v1.05. DNA samples with a
call rate,95% were excluded. The average call rate in the
remaining samples was 99.4%. From a total of 600,470 SNPs in
autosomal chromosomes (sex chromosomes, mitochondrial, and
pseudo-autosomal SNPs were excluded), the intensity-only probes
from chromosomes 1–22 were excluded (17,879), and 5,592 SNPs
were excluded by the PLINK algorithm. SNPs were included in
the imaging genetics analysis if their minor allele frequency (MAF)
was..05, were present for.90% of the subjects, and did not
depart from Hardy-Weinberg equilibrium for the controls using a
threshold of 1023. (Some SNPs were excluded for more than one
category). The final number of SNPs included in the analyses is
516,645.
Since the Illumina chip does not include the SNPs associated
with APOE alleles, a separate analysis was performed in which
DNA was extracted from 3 ml blood samples. APOE genotyping
was carried out on these samples by PCR amplification and HhaI
restriction enzyme digestion. The genotype was resolved on 4%
Metaphor Gel and visualized by ethidium bromide staining [21].
Statistical Analysis. Differences in clinical and demographic
values between these groups were analyzed by t test, chi-square or
Fisher exact test using STATA10 [22]. Population stratification
was examined with PLINK v1.5 and EIGENSTRAT [23,24] and
a lambda of 1.06 was observed, indicating no stratification.
Case-control analysis. Because APOE e4 is a well
documented risk factor for late onset AD, the Cochran-Armitage
trend test was used to analyze the APOE e4 allele (which are
results of ‘‘diplotypes’’ constructed on SNPs rs429358 and rs7412)
distribution between healthy controls and AD patients.
Based on the significance of our finding regarding APOE e4 in
our sample and recent interest in this region we expanded our
genotyping in the APOE region (,300-Kb on chromosome 19).
To increase the map density in the APOE region, we 1) merged
the results of the genotyping (performed with the APOE-specific
genotyping) of SNPs rs429358 and rs7412 and 2) performed
imputation. To impute the region, the set ‘‘hapmap_r23’’ was
downloaded from the HapMap site. This dataset includes 270
subjects from each one of the 4 populations studied by HapMap,
i.e. CEU, YRB and CHB+JPT for 267 SNPs [25]. The imputation
was considered successful for 159 SNPs with an in-silico call
rate.90% in this region. After imputation, the new dataset was
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used to calculate case-control association tests: 1) single marker
association and 2) haplotypes proxy association. The proxy
association test was calculated using the flanking markers in
strong LD with the ‘‘reference’’ SNP (i.e. proxies).
Quantitative Trait analysis. All autosomal SNPs that
passed quality control checks were tested for quantitative trait
association interaction using the general linear model as
implemented in PLINK v1.5. The statistical model is based on
comparing the differential effects of SNP association by diagnosis
on the brain imaging quantitative trait, i.e. the interaction term.
Based on the demographic analysis of our sample and the case-
control allelic association test for APOE e4, we covaried for age
and gender and for the number of APOE e4 alleles in the model.
Out of the possible 4 models to choose from (i.e. additive,
codominant, dominant and recessive) we a priori chose the additive
model as it is the most general, both reflecting the additive
contribution to risks for complex diseases [26], and detecting
strong non-additive effects.
The general linear model used to determine the interaction
term was:
Y~ b0 z b1:SNPz b2:APOE e4z b3:genderz b4:age
z b5:diagnosisz b6:SNP| diagnosisz e
in which bi represents the coefficients, SNP represents the genotype
of each marker tested, APOE e4 represents the allele dose of e4,
gender and diagnosis were coded as dichotomous variables, and
age is the age of the subject in years.
Our focus is on the SNP6diagnosis interaction. There is no
accepted method for determining a statistical threshold for a
quantitative trait interaction in a context of a genome-wide
association study (GWAS). Given 516,645 SNPs and the sample
size of 381 subjects, any result at 1026 or smaller provides
statistical evidence for a main effect associating a given SNP with a
quantitative trait. There is a lack of consensus on how to identify a
genome-wide significance threshold. Reaching a consensus
definition for an appropriate statistical threshold for the interac-
tion term in a GWAS is even more complex. For the purposes of
presenting the initial analyses of our data and considering the
small sample size, the number of variables analyzed and the
complexity of the model, we chose a conservative hypothesis for a
threshold of 1026 for our interaction term. In keeping with
recommendations for presenting a GWAS analysis [27] the results
of all analyses are provided in the supplemental material.
The Linkage Disequilibrium (LD) maps of each chromosomal
region harboring the most significant SNPs were created using a
window size of6200 Kb. D’ values were calculated using Haplo-
view 4.1 [28] and visualized with WGAViewer software, Version
1.25W; 2009 (http://www.genome.duke.edu/centers/pg2/down-
loads/wgaviewer.php) [29]. The genetic annotation was per-
formed using WGAViewer: SNPs location and gene names were
derived from Ensembl release 52 - Dec 2008 (http://www.
ensembl.org/) [30].
Results
Table 1 represents the demographic characteristics of the
sample analyzed. In this population the healthy control sample
had significantly more education than the AD sample, as well as
the expected differences in measures of cognitive performance.
Case Control analysis
The APOE e4 alleles were overrepresented in the AD cases as
expected (Cochran-Armitage test x2 (1 d.f.) = 62.3, p-val-
ue = 2.98610215). Of the two SNPs comprising the APOE
genotype, rs429358 SNP was significant at p-value = 2.30610216
and rs7412 at p-value = 5.0061024 (see Table 2). The second
most significant finding in the APOE region is the SNP rs2075650
(p-value = 7.4761027) located in intron 2 of TOMM40 gene. The
haplotype association via in silico reconstruction of proximal SNPs
increases the importance of the findings at this locus. One of the
haplotypes constructed with rs2075650 and the two flanking SNPs
rs11556505 (TOMM40) and rs429358 (APOE) has greater
significance (p-value = 1.50610211) than the univariate p-value
for the TOMM40 SNP.
QT analysis
The QT analysis identified 25 SNPs significant at the level
of#1026 associated with either the left or right hippocampal grey
matter volume (see Figure 1). A Q-Q plot of the association results
is presented in Figure 2. P-values from the observed distribution of
the test of interest (i.e., the SNPxDiagnosis interaction) are plotted
for all SNPs against the null distribution: p-values show a deviation
in excess in the upper tail distribution, suggesting the presence of
significant genetic association. Such deviation becomes evident at
a p,161026 supporting the hypothesis of a threshold for a claim
of genetic association at this significance value. The significant
SNPs (see Table 3) represent 15 loci and 6 desert regions. The QT
analysis for all SNPs is provided in the supplementary materials
Table 1. Baseline characteristic of mild AD subjects and healthy controls at baseline assessment.
Category Control AD p-Value
Number of Subjects 209 172
Gender (Male/Female) 108/101 91/81 $0.81 Chi Square
Age 75.8765.10 75.3167.32 $0.39
MMSE 29.0961.00 23.3362.06 ,0.0001
ADASCog 9.3364.14 27.6369.58 ,0.0001
Years of Education 15.9962.90 14.7463.15 ,0.0001
Handedness (right/left) 191/18 162/10 $0.29 Chi Square
Ethnicity (Hispanic/non-Hispanic/unknown) 1/205/3 4/166/2 $0.327 Fisher’s exact
Race (African American/Asian/More than one race/White) 14/3/0/192 7/1/2/162 $0.256 Fisher’s exact
APOE (e2/e3/e4) 34/322/62 8/194/142 ,0.0001 Chi Square
doi:10.1371/journal.pone.0006501.t001
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Table 2. Case – control association results in the region of interest harboring APOE gene.
Gene SNP Coordinate (Build 36.3) Type Consequence Type Allele frequency [%] cases/controls p-Value
TOMM40 rs8102977 50085313 imputed 59UTR 2.3/1.3 0.3
TOMM40 rs157580 50087106 genotyped intronic 73.8/62.7 1.1061023
TOMM40 rs2075650 50087459 genotyped intronic 29.9/15.1 7.4861027
TOMM40 rs11556505 50087984 imputed synonymous-coding 26.5/14.3 2.9661025
TOMM40 rs8106922 50093506 genotyped intronic 70.6/64.8 0.08
TOMM40 rs1160985 50095252 imputed intronic 58.7/52.0 0.07
APOE rs405509 50100676 genotyped 59UTR 57.6/49.3 0.02
APOE rs769451 50102751 genotyped intronic 98.8/97.6 0.21
APOE rs429358 50103781 genotyped non-synonymous-coding 41.3/14.9 2.30610216
APOE rs7412 50103919 genotyped non-synonymous-coding 97.7/91.9 5.0061024
LOC100129500 rs439401 50106291 genotyped intronic 75.0/62.9 4.0061024
LOC100129500-APOC1 rs5114 50110286 imputed intronic 1.00/99.5 0.19
LOC100129500-APOC1 rs389261 50112183 imputed intronic 98.3/96.4 0.15
LOC100129500-APOC1 rs10424339 50112333 imputed intronic 99.0/98.9 0.92
LOC100129500-APOC1 rs12721054 50114427 imputed intronic 1.00/99.5 0.2
Case control association analysis in the APOE region with special focus on TOMM40, APOE and APOC1 genes. Gene name, SNP name (rs number), SNP base-pair position
(build 36.3), genotype type (either obtained through actual genotyping or through in silico imputation), physical location or SNP function (consequence type), case-
control allele frequencies and p-values ordered by base-pair position.
doi:10.1371/journal.pone.0006501.t002
Figure 1. Manhattan plot of the quantitative trait genome wide association analysis. Manhattan plot of the p-values (-Log10(Observed p-
value)) from the QT (right hippocampus) genome-wide association analysis. The spacing between the SNPs does not reflect the actual distances
between SNPs in the genome. Each color identifies an autosomal chromosome (from chromosome 1 to chromosome 22). The horizontal lines display
the cutoffs for 3 significance levels: green line for mild significance (1023,p,1025), blue line for high significance (1025,p,1026) and red line for
genome-wide significance level (p,1026). Different symbols reflect the function of the SNPs as detailed here: ‘‘m’’ intronic, ‘‘&’’ 39UTR or
downstream region, ‘‘+’’ 59UTR or upstream region, ‘‘o’’ synonymous coding, ‘‘*’’ non-synonymous coding, ‘‘N’’ intergenic.
doi:10.1371/journal.pone.0006501.g001
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(see Supplementary files). Of the 25 significant SNPs, thirteen map
directly in genes and pseudogenes or are linked based on the LD
structure of the region. Four SNPs map in regions characterized
by a high level of genomic complexity given the overlap of several
different genes and isoforms or pseudogenes in these areas. Eight
SNPs map to 6 different ‘‘desert’’ regions where no specific gene
annotation could be found including the LD block structure of the
region. Details of these 25 significant SNPs follow. Supporting
figures (Figures S1 – Figure S20) and tables (Table S1 – Table S20)
are available for each of the 25 significant SNPs.
Two of the most significant SNPs, rs10074258 and rs12654281,
are both related to the gene EFNA5 (p-value= 2.1561027and
3.7261027 respectively). The LD pattern of this region allows the
identification of a 61-Kbp LD block that harbors the 59 end of the
EFNA5 gene. Eleven out of the 16 SNPs in this genomic area are
nominally significant (1026,p,.05) providing additional support
for the involvement of EFNA5 in AD. Six more nominally
significant SNPs (1024,p,1023) are located in a ,31-Kbp LD
block on the same chromosome, 64 Kbp upstream the gene and
containing the pseudogene AC024587.5 characterized by 2
isoforms partially overlapping in the genome. The two isoforms
may have different functions according to the biotype description:
the first one is a scRNA pseudogene and the second is miscellaneous
pseudogene.
SNP rs10781380 is in the gene PRUNE2, which spans a total of
117-Kbp and includes 44 SNPs. An additional six nominally
significant (1024,p,1023) SNPs are located in the same 41-Kbp
LD block that includes 15 SNPs in introns 6, exon 7 and the
downstream region of the gene. PRUNE2 has two partially
overlapping isoforms.
SNP rs8115854 is associated at the GWAS threshold significance
level of 1026. This SNP is a non-synonymous coding polymorphism
(I509T or I474T) mapping C20orf132 that shows 4 different
isoforms and encodes for the hypothetical protein LOC140699.
The C20orf132 gene spans a total of ,78-Kbp and 7 SNPs were
genotyped successfully in our sample. The most significant SNP (p-
value= 2.0961026) is responsible for a threonine to isoleucine
substitution. Three additional SNPs, rs8120307, rs1780682 and
rs1744760 are nominally significant (1025,p,1023) and are
located in intron 1 and 8 and exon 19 respectively. SNP
rs1744760 (Q836R) (p-value= 1.761023) is another non-synony-
mous (arginine-glutamine) coding SNP. This gene is located in a
,230-kbp genomic region characterized by a high degree of LD
that contains several overlapping different genes: RBL1 (2 isoforms),
RPS3AP3, RPS27AP3, RP3-343K2.4 and RPN2 (7 isoforms). This
genomic region includes 10 SNPs beside the 7 located in
C20orf132. SNP rs6031882 (p-value= 6.2061026) is located in
intron 1 of RPN2. Two out of these total 10 SNPs are also nominally
Figure 2. Q-Q plot of the quantitative trait genome wide association analysis. Q-Q plot of the quantitative trait genome wide association
analysis for both right hippocampus (red dots) and left hippocampus (violet dots).
doi:10.1371/journal.pone.0006501.g002
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significant (1025,p,1023): rs1892205 and rs3897903 are located
in intron 2 and 12 of RBL1.
SNP rs2073145 (p-value = 2.1361026) is a non-synonymous
coding polymorphism (E88K) responsible for a glutamic acid (E)
by lysine (K) substitution in the ZBP1 gene that encodes a Z-DNA
binding protein. This SNP is located in a 26-Kbp LD block that
encompasses only the 59 upstream region of the gene and where 7
out of 10 SNPs are nominally significant (1024,p,.05).
SNP rs10867752 (p-value = 3.0861026) is located,8 kbp distal
from the upstream of the pseudogene RP11-232A1.1 on
chromosome 9. Its 27-Kbp LD block also contains 5 out of 8
SNPs nominally significant (1025,p,1023). The genomic region
downstream from the pseudogene is characterized by a high
degree of LD. The QC filters did not allow the calculation of the
statistics for most of the SNPs that are included in this ,73-Kbp
LD block.
SNP rs1082714 (p-value = 4.9361026) is located 34-Kbp from
the 59 end of CAND1 gene on a large LD block that also includes
the gene itself. Thus, a synonymous-coding SNP rs1060350
(L1183L) of CAND1 (p-value = 0.02) might acquire relevance.
Four other SNPs map to a similar number of genes, in all cases
also showing other nominally significant SNPs in addition to those
that present a genome-wide significance. In particular, SNP
rs337847 is related to the ARSB gene, SNP rs682748 to the
processed pseudogene AC026790.5 (with 9 out of 14 SNPs
significant). SNP rs1364705 is related to the gene MAL2 and SNP
rs11525066 to the gene MAGI2.
The four complex regions are characterized by the overlap of
many different genes, isoforms of the same genes or pseudogenes.
SNP rs6881634 (p-value = 1.9361026) identifies a locus of interest
in an apparently conserved region of ,190-Kbp in chromosome 5
containing several different pseudogenes and genes: AC104108.3,
SCAMP1 (3 isoforms), LHFPL2 (2 isoforms). The most significant
SNP is located ,14-Kbp from AC104108.3 but is also in strong
LD (D’ = 1) with the first typed SNP located at the upstream of the
SCAMP1 gene. This genomic region includes 13 other SNPs out
of 33 that are nominally significant (1025,p,1023) beside the top
SNP.
SNP rs11626056 (p-value = 1.1861026) is located in a 35-Kbp
genomic region of chromosome 14 characterized by a very low
degree of LD that harbors two isoforms of the same gene
AL079307.7: a retrotransposed gene and a pseudogene. Due to
the low degree of LD and the few SNPs typed that passed QC, it is
not possible to link this SNP to any annotated genes. The genomic
area surrounding this locus seems conserved based on the LD
pattern, though, and might be of interest as it contains 2 additional
isoforms of the same olfactory receptor pseudogene (OR7E) with
different functions (i.e. rRNA and snRNA) overlapping with the
gene FRMD6.
SNP rs4845552 (p-value = 6.2361026) on chromosome 1 is
located ,7-Kbp from the locus AL157404.18, hypothetically
coding a transcription regulatory misc RNA. This misc RNA is
located in a conserved region characterized by high LD that
contains several additional genes and their different isoforms:
S100A5 (3), S100A4 (4), S100A3 (2) and S100A2 (5). None of the
SNPs belonging to the S100A family genes passed QC filters.
SNP rs1373549 (p-value = 7.8061026) on chromosome 12 is
intergenic and identifies a locus of interest encompassing several
different pseudogenes and genes: ARID2 (2 isoforms), SFRS2IP (4
isoforms) and the pseudogene AC009464.8. The most significant
SNP is located ,100-Kbp downstream SFRS2IP in a genomic
region characterized by a high degree of LD. In the same region
(from 44802396 bp to 44420742 bp) 22 out of 32 SNPs are
nominally significant (1025,p,1023) beside the top SNP.
The 8 remaining top SNPs identify 6 loci of interest located in
genomic regions characterized by the absence of known annotated
genes, so called ‘‘desert’’ regions. Five out of the 8 significant
findings are between 60 to to 200 Kbp from the closest annotated
genes or pseudogenes. SNPs rs1888414 is located ,16-Kbp and
rs10276619 and rs2124799 are located ,31-Kbp from the closest
genes, FDPSP and IKFZ1 respectively. These SNPs, however, are
not in an LD region for either gene.
Discussion
The goal of this paper was to present an initial QT analysis
combining imaging and genetic data obtained in a GWAS from
the ADNI cohort, in addition to a standard case-control analysis.
Our aim was to make publicly available genotype data for AD and
controls in the context of rich multimodal imaging data and
comprehensive clinical data that can be investigated by the
research community, as well as conducting a preliminary analysis
to identify potential genes related to the susceptibility of AD. The
case-control analysis confirmed the association with APOE alleles,
as expected, and also implicated TOMM40, a gene physically
close to APOE that contributes additional risk to developing AD
[31,32] (TOMM40, translocase of outer mitochondrial membrane
40) influences mitochondrial function. Aging both decreases the
number of mitochondria and increases risk of developing AD.
TOMM40 alleles have been recently linked to an earlier onset of
AD (Roses AD et al.: ‘‘Apoe-3 And Tomm-40 Haplotypes
Determine Inheritance Of Alzheimer’s Disease Independently
Of Apoe-4 Risk’’. Alzheimer’s Association 2009 International
Conference on Alzheimer’s Disease, July 12, 2009).
The application of a QT analysis for the interaction of
genotypes with diagnosis, however, allowed us to identify novel
candidate genes at high levels of genome-wide significant SNPs.
We found a strong main effect for the APOE e4 allele on the
hippocampal volume. However, we did not find a diagnosis by
allele interaction relative to APOE e4, suggesting that APOE
alleles affect hippocampal volume similarly in both AD patients
and healthy controls. This is consistent with most, but not all, of
the literature finding an association of APOE e4 with accelerated
age-related volume loss in hippocampus and several other brain
regions as well as in AD [33–36]. These results suggest an effect of
APOE 4 on the brain atrophy, independent from its overrepre-
sentation in AD.
The rationale of this study is that hippocampal atrophy in AD
subjects is more objective and closer to the genes contributing to
AD than the clinical subjective diagnosis of AD alone. Hippo-
campal atrophy is characterized by neuronal loss and decreased
synaptic density and is believed to be caused by the accumulation
of neuropathological events in addition to the observed amyloid
and tau pathology [37]. Apoptosis, cell cycle impairment and the
alteration of protein folding and degradation through ubiquination
are among the candidate pathophysiological mechanisms that may
underlie neurodegeneration in AD [38–45]. Based on our
preliminary functional annotation, our significant SNPs related
to genes PRUNE2, MAGI2, ARSB, EFNA5, CAND1 may be
associated with these biochemical and cellular changes.
We found associations between hippocampal volume reductions
in AD subjects and the EFNA5 (ephrin-A5), ARSB (arylsulfatase
B), MAGI2 (membrane associated guanylate kinase, WW and
PDZ domain containing 2), PRUNE2 (prune homolog 2), and
CAND1 (cullin-associated and neddylation-dissociated 1) genes.
These genes are associated with the aforementioned biochemical
processes, namely ubiquination (MAGI2, CAND1), apoptosis
(CAND1, PRUNE2), oxidative necrosis (ARSB), hippocampal
Imaging Genetics in AD
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6501
development (EFNA5), and dementia, (MAGI2, ARBS). The
presence of the highly conserved BCH domain (BNIP2 and
Cdc42GAP homology) in PRUNE2 which is involved in a variety
of protein-protein interactions and the presence of the BNIP-2
domain, a substrate for caspase cleavage suggest a role for
PRUNE2 in apoptosis [46]. CAND1 allows the complex
formation between CUL1 and SKP [47]. Cullins (CUL) are
scaffold proteins for the ubiquitin ligase complex, and neddylation
of cullin enhances its ability to promote ubiquitination [48].
NEDD8 has been found in ubiquitinated neurofibrillary tangles in
the AD brain [49]. The conjugation of NEDD8 is stimulated by
the interaction of APP with APP-BP1 that mediates APP-induced
apoptosis in the AD brain [50].
MAGI2, together with ATN1 (atrophin 1), has been implicated in
Dentato-Rubral and PallidoLuysian Atrophy (DRPLA), a disease
with a syndrome of myoclonic epilepsy, dementia, ataxia, and
choreoathetosis [51]. MAGI2 has been speculated to play a critical
role in the ubiquitination process of ATN1 by linking ubiquitinating
enzyme to plasma membrane proteins, neurotransmitter receptors
and ion channels [51]. Perturbation of the ubiquitin system could
potentially lead to increased misfolded protein accumulation and
cell cycle abnormalities, and apoptosis [52].
The gene EFNA5 is highly expressed in the human brain and
hippocampus. Ephrin-A5 is a member of the Ephrin (Eph)
superfamily implicated in mediating developmental events in the
nervous system [53,54]. The Ephrin family of receptors regulates
cell morphology and behavior by rearranging the actin cytoskel-
eton through the Rho family of small G-proteins [55]. Eph-A
receptor signaling has been directly implicated in axon guidance,
while Eph-B receptor signaling has been linked to dendritic spine
morphogenesis [56]. EFNA5 and its interactions with other axon
guidance genes have been linked to susceptibility to developing
Parkinson’s disease [57]. It is possible that the EFNA5 findings are
consistent with a neurodevelopmental process in both AD and
Parkinson’s disease.
ARSB (Arylsulfatase B) is a lysosomal enzyme that removes the
sulfate ester group of N-acetylgalactosamine-4-sulfate in dermatan
and chondroitin sulfate. A mutation in this enzyme leads to the
development of the lysosome storage disease called mucopolysac-
charidosis VI [58]. The accumulation of amyloid b peptide (A\) is
toxic to neuronal cells by inducing oxidative stress [59]. In
response to oxidative stress, alterations of various endosomal-
lysosomal components including ARSB have been observed in AD
brains [60,61]. This fact could support the hypothesis that ARSB
is involved in the modulation of the oxidative stress pathway and
neuronal loss in the development of AD.
Our results highlight the variety of data that can be obtained
from these different analytic approaches. Previous GWASs in AD
using a categorical approach have not been able to consistently
identify risk genes in AD other than APOE [62]. To further
evaluate our finding of no interaction with diagnosis and APOE
we performed a QT analysis removing APOE–related SNPs. The
results of the analysis were very similar with the addition of a single
SNP, rs8027305 in THSD4, significant at p#1026.
It is important to emphasize that the SNPs from the Illumina
Human610-Quad BeadChip are tagging SNPs and as such
represents ‘‘flags’’ for a possible location of a susceptibility locus
to AD, and rarely – if ever – are the causal SNPs. The advantage
of a tagging SNPs approach is that it maps an average 10 to max
20 kilobases in which a causal DNA variant may be found, thus
indicating an area of focus for gene sequencing and subsequent
studies of molecular mechanisms. The genes that we identified by
surrogate SNPs are candidates that require additional confirma-
tion in independent samples. Our method using brain imaging as a
quantitative trait is fundamentally different from case-control
approaches as it begins with brain imaging as a dependent variable
and then identifies as genes that affect the brain imaging
differences between AD and healthy controls. This is a very
different contrast than comparing frequencies of genotypes across
cases and controls and therefore is not expected to identify the
same results as a QT approach. Interestingly, some of our findings
are located in putative hot spots regions for AD, previously
identified by other investigators using case-control, linkage and
other methods. These overlapping hot spots include regions on
chromosomes 5 [63], 9 [64–66], and 14 [67].
The sample only contained mild AD patients, a relatively
narrow range of illness, and therefore is not fully representative of
the disease. Also, the ADNI sample was not collected under an
epidemiological ascertainment strategy and the sample size itself is
small, further limiting its generalizability. The small sample size,
however, was somewhat mitigated by the four to eightfold increase
in statistical power of a quantitative trait design over a categorical
case-control analysis [4,68]. Our case control analysis suffered
from inadequate power relative to the more powered QT analysis.
Nevertheless, the possibility of false positives remains. Also, there is
no a definitive established method for determining appropriate
statistical threshold values for an interaction term (i.e., SNP6diag-
nosis) in a QT analysis in the context of a genome-wide scan. Our
solution was to consider the physical clustering of SNPs and their
biological plausibility and to report the full extent of our findings in
the paper and supplemental tables. This allows the reader to
consider our preliminary results in terms of their statistical and
biological consistency given the multiple testing issues. This is
similar to the strategy used by Almasy et al. 2008 [69].
Hippocampal volume was chosen as our quantitative phenotype
because of its sensitivity to the changes of early AD disease [70].
Clinical diagnosis of AD in part depends on subjective reporting
by the patient and caretaker. The clinical presentation may be
more distal from the underlying genetic causes than the brain
atrophy that usually predates symptoms by many years. Identify-
ing genes that contribute to hippocampal atrophy have the
potential to identify novel genes and pathways involved in the
development of Alzheimer’s disease at its earliest stages. It is
possible that other brain imaging phenotypes would identify other
candidate genes.
Conclusion
This QT study is a cross-sectional analysis of baseline
hippocampal grey matter density with common genetic variants
as measured by SNP genotypes in the ADNI sample. A QT
analysis provides a powerful strategy for gene discovery in the
context of a genome-wide survey. ADNI provides longitudinal
clinical, cognitive, biomarker and imaging data which will
facilitate the search for genes that are associated with conversion
from normal to MCI and from MCI to AD, as well as the rates of
change within and between these categories. The goal of this
preliminary analysis was to identify unanticipated risk genes for
the development of mild AD as represented by hippocampal
atrophy. Elucidating the roles of PRUNE2, MAGI2, ARSB and
EFNA5 in the regulation of neurodevelopment, protein degrada-
tion, apoptosis and neuronal loss could enhance our understanding
of hippocampal atrophy and AD. This method of gene discovery
complements other established strategies such as case-control
designs with large sample sizes, family-based design, and targeted
candidate gene approaches. To address the concerns of multiple
testing and false positive findings, all genotyped data are publicly
available (LONI, http://www.loni.ucla.edu/ADNI/Data/) for
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combining with other datasets and for other analytical approaches
by the scientific community.
Supporting Information
Figure S1 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s001 (0.80 MB TIF)
Figure S2 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s002 (0.85 MB TIF)
Figure S3 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s003 (0.71 MB TIF)
Figure S4 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s004 (0.87 MB TIF)
Figure S5 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s005 (0.95 MB TIF)
Figure S6 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s006 (0.85 MB TIF)
Figure S7 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s007 (0.87 MB TIF)
Figure S8 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
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right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s008 (0.90 MB TIF)
Figure S9 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s009 (0.82 MB TIF)
Figure S10 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s010 (0.57 MB TIF)
Figure S11 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s011 (1.01 MB TIF)
Figure S12 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s012 (0.78 MB TIF)
Figure S13 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s013 (0.95 MB TIF)
Figure S14 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s014 (1.20 MB TIF)
Figure S15 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s015 (0.82 MB TIF)
Figure S16 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
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of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s016 (0.93 MB TIF)
Figure S17 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s017 (0.79 MB TIF)
Figure S18 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s018 (0.98 MB TIF)
Figure S19 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s019 (0.90 MB TIF)
Figure S20 QT analysis of SNPs associated with genes or
chromosomal regions as reported in Table 3 of the manuscript.
Physical map of the SNPs associated with genes or chromosomal
regions in the ADNI sample produced by WGAViewer. The top
of the figure is the ideogram of the chromosome; the vertical red
line depicts the relative location of locus of interest. Below the
graph are the -log p significance values of the individual SNPs on
the imaging phenotype (hippocampal atrophy) for the left and
right hemispheres as indicated in each figure. The blue lines below
the graph indicate the location of the exons in the transcripts
annotated (translated region of the DNA). The vertical lines above
the accompanying triangular matrix indicate the SNP locations,
and demonstrate the LD pattern between SNPs (D’). The warmer
colors on the flame scale indicate greater LD while the blue
indicates absence of LD.
Found at: doi:10.1371/journal.pone.0006501.s020 (0.90 MB TIF)
Table S1 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s021 (0.03 MB
XLS)
Table S2 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The SNP
chromosome, gene, base-pair position, rs number, consequence
type and SNP alleles are presented. The p-values for the left and
right hippocampi indicate the interaction between SNP and
diagnosis in explaining the subjects’ degree of hippocampal atrophy.
Found at: doi:10.1371/journal.pone.0006501.s022 (0.04 MB
XLS)
Table S3 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s023 (0.03 MB
XLS)
Table S4 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The SNP
chromosome, gene, base-pair position, rs number, consequence
type and SNP alleles are presented. The p-values for the left and
right hippocampi indicate the interaction between SNP and
diagnosis in explaining the subjects’ degree of hippocampal atrophy.
Found at: doi:10.1371/journal.pone.0006501.s024 (0.04 MB
XLS)
Table S5 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s025 (0.04 MB
XLS)
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Table S6 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The SNP
chromosome, gene, base-pair position, rs number, consequence
type and SNP alleles are presented. The p-values for the left and
right hippocampi indicate the interaction between SNP and
diagnosis in explaining the subjects’ degree of hippocampal atrophy.
Found at: doi:10.1371/journal.pone.0006501.s026 (0.04 MB
XLS)
Table S7 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s027 (0.04 MB
XLS)
Table S8 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s028 (0.04 MB
RTF)
Table S9 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s029 (0.04 MB
XLS)
Table S10 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s030 (0.03 MB
XLS)
Table S11 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The SNP
chromosome, gene, base-pair position, rs number, consequence
type and SNP alleles are presented. The p-values for the left and
right hippocampi indicate the interaction between SNP and
diagnosis in explaining the subjects’ degree of hippocampal atrophy.
Found at: doi:10.1371/journal.pone.0006501.s031 (0.04 MB
XLS)
Table S12 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s032 (0.04 MB
XLS)
Table S13 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s033 (0.04 MB
XLS)
Table S14 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s034 (0.04 MB
XLS)
Table S15 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s035 (0.04 MB
XLS)
Table S16 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s036 (0.04 MB
RTF)
Table S17 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s037 (0.04 MB
XLS)
Table S18 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
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quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s038 (0.04 MB
XLS)
Table S19 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s039 (0.04 MB
XLS)
Table S20 Quantitative trait analysis for the interaction between
left and right hippocampi for the SNPs and related genes or
chromosomal regions listed in Table 3 of the manuscript. The
SNP chromosome, gene, base-pair position, rs number, conse-
quence type and SNP alleles are presented. The p-values for the
left and right hippocampi indicate the interaction between SNP
and diagnosis in explaining the subjects’ degree of hippocampal
atrophy.
Found at: doi:10.1371/journal.pone.0006501.s040 (0.04 MB
XLS)
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